{
    "Clinical Trial ID": "NCT00075764",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I Anastrozole",
        "  Patients receive oral anastrozole once daily on days 1-28.",
        "  anastrozole: Given orally",
        "INTERVENTION 2: ",
        "  Arm II Anastrozole and Fulvestrant",
        "  Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.",
        "  anastrozole: Given orally",
        "  fulvestrant: Given intramuscularly"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed breast cancer meeting 1 of the following criteria:",
        "  Metastatic disease (M1)",
        "  Multiple sites of new disease that is clinically obvious metastatic disease (e.g., multiple sites of new osseous disease)",
        "  Measurable or nonmeasurable disease",
        "  No known brain or CNS metastases",
        "  Hormone receptor status:",
        "  Estrogen-receptor positive* AND/OR",
        "  Progesterone-receptor positive* NOTE: *Positivity defined as estrogen binding of > 10 fmol/mg cytosol protein by ligand binding assay or positive by immunohistochemistry",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  Not specified",
        "  Sex",
        "  Female",
        "  Menopausal status",
        "  Postmenopausal, as defined by 1 of the following:",
        "  Prior bilateral oophorectomy",
        "  More than 12 months since last menstrual period with no prior hysterectomy",
        "  At least 55 years of age with prior hysterectomy",
        "  Under 55 years of age with a prior hysterectomy without oophorectomy and with estradiol and follicle-stimulating hormone levels consistent with menopause",
        "  Performance status",
        "  Zubrod 0-2",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  No bleeding diathesis (e.g., disseminated intravascular coagulation or clotting factor deficiency)",
        "  Hepatic",
        "  INR  1.6",
        "  Renal",
        "  Not specified",
        "  Other",
        "  HIV negative",
        "  No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  No prior immunotherapy for recurrent or metastatic disease",
        "  Chemotherapy",
        "  No prior chemotherapy for recurrent or metastatic disease",
        "  More than 12 months since prior adjuvant or neoadjuvant chemotherapy",
        "  No concurrent chemotherapy for malignancy",
        "  Endocrine therapy",
        "  Prior adjuvant hormonal therapy allowed",
        "  At least 12 months since prior adjuvant luteinizing hormone-releasing hormone (LHRH) analogues",
        "  Menstrual periods must not have resumed since LHRH therapy",
        "  More than 12 months since prior adjuvant or neoadjuvant aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane)",
        "  More than 12 months since prior fulvestrant",
        "  No prior hormonal therapy for recurrent or metastatic disease",
        "  No other concurrent hormonal therapy for malignancy",
        "  No concurrent hormone replacement therapy",
        "  Radiotherapy",
        "  Not specified",
        "  Surgery",
        "  Not specified",
        "  Other",
        "  No long-term anticoagulant therapy (except antiplatelet therapy)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Tumor Progression",
        "  Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration. From date of randomization to time of first documentation of progression, symptomatic deterioration or death due to any cause. Patients last known to be alive and progression free are considered at last date of contact.",
        "  Time frame: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.",
        "Results 1: ",
        "  Arm/Group Title: Arm I Anastrozole",
        "  Arm/Group Description: Patients receive oral anastrozole once daily on days 1-28.",
        "  anastrozole: Given orally",
        "  Overall Number of Participants Analyzed: 345",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  13.5        (12.1 to 15.1)",
        "Results 2: ",
        "  Arm/Group Title: Arm II Anastrozole and Fulvestrant",
        "  Arm/Group Description: Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.",
        "  anastrozole: Given orally",
        "  fulvestrant: Given intramuscularly",
        "  Overall Number of Participants Analyzed: 349",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  15.0        (13.2 to 18.4)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 21/337 (6.23%)",
        "  Blood/Bone Marrow-Other 0/337 (0.00%)",
        "  Febrile neutropenia 0/337 (0.00%)",
        "  Hemoglobin 2/337 (0.59%)",
        "  Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%)",
        "  Cardiac-ischemia/infarction 1/337 (0.30%)",
        "  Left ventricular diastolic dysfunction 0/337 (0.00%)",
        "  Left ventricular systolic dysfunction 1/337 (0.30%)",
        "  Restrictive cardiomyopathy 1/337 (0.30%)",
        "Adverse Events 2:",
        "  Total: 48/348 (13.79%)",
        "  Blood/Bone Marrow-Other 1/348 (0.29%)",
        "  Febrile neutropenia 1/348 (0.29%)",
        "  Hemoglobin 1/348 (0.29%)",
        "  Atrioventricular block - 2nd degree Mobitz Type II 1/348 (0.29%)",
        "  Cardiac-ischemia/infarction 2/348 (0.57%)",
        "  Left ventricular diastolic dysfunction 1/348 (0.29%)",
        "  Left ventricular systolic dysfunction 0/348 (0.00%)",
        "  Restrictive cardiomyopathy 0/348 (0.00%)"
    ]
}